Evaluation
of Cardioprotective Potential of Drakshasava
in Induced Diabetic Condition
Preeti Tiwari1*,
Rakesh K. Patel2 and T.S. Eashwari3
1Head of Department of
Pharmacognosy and Phytochemistry, IIMT College of
Medical Sciences, Meerut, (U.P.) India
2Head of Department of
Pharmacognosy, Shri S. K. Patel College of
Pharmaceutical Education and Research, Kherva-382711, Gujarat, India
3Director (Pharmacy),
IIMT College of Medical Sciences, Meerut, (U.P.) India
ABSTRACT:
The objective of the present study was to
evaluate the effect of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods
respectively and marketed Drakshasava on fasting
blood glucose and serum lipid profile in alloxan
induced diabetic rats. Oral administration of Drakshasava-T,
Drakshasava-M and marketed Drakshasava (2 ml/kg p.o.) for
21 days caused a significant decrease in fasting blood glucose (FBG) and showed
significant rise in blood glutathione level (GSH) in diabetic rats. Glibenclamide was used as a standard antidiabetic
drug (10 mg/kg, p.o). These preparations also caused
significant reduction in serum cholesterol, LDL and triglycerides and showed
significant rise in serum HDL level in diabetic albino rats. Thus all these
preparations were able to maintain the tested parameters near to the normal
level significantly.
KEYWORDS: Cardiovascular risk, Blood glucose,
anti-diabetic potential, glutathione, lipid profile, Drakshasava,
alloxan.
1. INTRODUCTION:
Diabetics have accelerated levels of
oxidative stress and this contributes massively to most cardiovascular,
neurological, retinal and renal diabetic complications1. Diabetes
mellitus is a heterogeneous metabolic disorder as old as mankind and its
incidence is considered to be high all over the world2. It is
characterized by hyperglycemia. Hyperglycemia significantly diminishes
glutathione levels lowering defences against
oxidative stress3.
A multitude of herbs, spices and other plant
material has been described for the treatment of diabetes throughout the world4.
Furthermore, after the recommendations made by WHO (World Health Organization)
on diabetes mellitus, investigations on hypoglycaemic
agents from medicinal plants have become more important. The levels of serum
lipids are usually elevated in diabetes mellitus and such an elevation
represents the risk factor for coronary heart disease. Moreover, diabetic
patients experience a two to three fold increase in cardiovascular morbidity
and mortality in comparison to non diabetics5.
Drakshasava is a polyherbal hydroalcoholic
preparation and is used to improve digestion, as blood purifier, in the
treatment of anaemia and advised as a choice of
remedy in respiratory problems. The chief ingredient of Drakshasava
is draksha, dried fruits of Vitis vinifera6.
The composition and properties of fruits of Vitis vinifera have been extensively
investigated and it was reported that they contain large amount of phenolic compounds as catechins, epicatechin, quercetin and gallic acid, dimeric, trimeric and tetrameric procyanidins7-8.
These compounds have many favourable effects on human
health such as lowering of human low density lipoproteins, reduction of heart
disease and cancer because of their antioxidant property9-16.
Therefore we undertook the present investigation
to evaluate the antidiabetic effect of Drakshasava-T and Drakshasava-M
prepared by traditional and modern methods respectively and also marketed Drakshasava in alloxan induced
hyperglycemic rats. Effect of these preparations was also evaluated on the
serum lipid profile of alloxan induced diabetic rats.
2.
MATERIALS AND METHOD:
2.1
Preparation of Drakshasava-T
This was prepared by the method as given in Ayurvedic Formulary of India, Part-II6. The
ingredients were procured from local market, Jamnagar. Identification of
individual plant material was done as per Ayurvedic
Pharmacopoeia of India. Authentication of all these ingredients was done by Dr.G. D. Bagchi, Scientist,
Department of Taxonomy and Pharmacognosy, Central Institute of Medicinal and
Aromatic Plants, Lucknow. Prepared herbarium has been
deposited in CIMAP for future reference.
According to this method, dried fruits of Vitis vinifera were
crushed and then placed in polished vessel of brass along with prescribed
quantity of water (16.384 L), and allowed to steep overnight. After overnight
steeping, this material was warmed at medium flame until the water for
decoction reduced to one fourth of the prescribed quantity (4.096 L), then the
heating was stopped and it was filtered through unstarched
muslin cloth in cleaned and fumigated vessel and after that jaggery
and honey were added and mixed properly. Then dhataki
flowers (Woodfordia floribunda) and prescribed quantity of
coarsely powdered prakshepa dravyas
as Myristica fragrans (flowers),
Eugenia caryophyllus
(flower bud), Cubeba officinalis (fruits),
Santalum album (heart wood), Piper nigrum
(fruits), Cinnamomum zeylanicum
(stem bark), Eletteria cardamomum
(seeds) and Cinnamomum tamala
(leaves) were added and this sweet filtered fluid was placed for fermentation
in incubator for fifteen days at 33ºC± 1ºC.
After fifteen days, completion of fermentation was confirmed by standard
tests17. The fermented preparation was filtered with unstarched muslin cloth and kept in cleaned covered vessel
for further next seven days. Then, it was poured in clean amber colored glass
bottles previously rinsed with ethyl alcohol, packed and labelled
properly.
2.2
Preparation of Drakshasava-M:
Method of preparation was same as followed
with Drakshasava-T, only dhataki
flowers were replaced with yeast for inducing fermentation18.
2.3
Drugs and Chemicals:
Alloxan monohydrate was
purchased from Loba Chemie,
Mumbai. Standard antidiabetic drug glibenclamide was obtained from Ranbaxy Research
Laboratories, Gurgaon, India.
2.4
Animals:
Adult Wistar albino
rats, weighing between 200-220g of either sex were acclimatized to normal
environmental conditions in the animal house for one week. The animals were
housed in standard polypropylene cages and maintained under controlled room
temperature (22 oC±2oC) and humidity (55±5%) with 12:12
hour light and dark cycle. All the animals were given a standard chow diet
(Hindustan Lever Limited), and water ad libitum. The guidelines of the Committee for the
Purpose of Control and Supervision of Experiments on Animals (CPCSEA) of the
Government of India were followed and prior permission was granted from the
Institutional Animal Ethics Committee of Shri Sarvajanik Pharmacy College, Mehsana
(CPCSEA No. 07/09).
2.5
Induction of Diabetes:
The animals were fasted for 18 h and made
diabetic by injecting Alloxan monohydrate (150mg/kg, i.p.) dissolved in sterile normal saline. In order to stave
off the hypoglycaemia during the first day, 5% w/v
glucose solution was given orally to diabetic rats after four to six hours of alloxan administration. The diabetic state was confirmed
when the blood sugar level was greater than 180 mg/dl19 .
2.6
Treatment Protocol:
All the animals were randomly divided into
the six groups with six animals in each group. All the three types of Drakshasava as Drakshasava-T, Drakshasava-M and marketed Drakshasava
were given at a dose of 2 ml/kg body weight, orally daily for a period of 21
days to different groups of diabetic animals.
Group I
: Normal animals received normal saline as vehicle (2 ml/kg, p.o.)
Group II : Diabetic animals received normal
saline as vehicle (2 ml/kg, p.o.)
Group III : Diabetic animals received glibenclamide (10 mg/kg, p.o.)20
Group IV : Diabetic animals received Drakshasava-T (2 ml/kg, p.o.)
Group V : Diabetic animals received Drakshasava-M (2 ml/kg, p.o.)
Group VI
: Diabetic animals received marketed Drakshasava
(2 ml/kg, p.o.)
Albino rats were made diabetic by a single
intra-peritonial injection of alloxan
monohydrate (Loba Chemie,
Mumbai). Alloxan was first weighed individually for
each animal according to the weight and then solubilized
with 0.2ml saline just prior to injection. Two days after Alloxan
monohydrate injection rats with blood glucose level of greater than 180mg/dl
were selected for the present study. Treatment with Drakshasava-T,
Drakshasava-M and marketed Drakshasava
was started 48h after alloxan injection. Blood
samples were drawn at weekly interval until the end of study i.e three weeks. Fasting blood glucose (FBG), blood
glutathione (GSH) estimation and body weight measurement were done on day 1st,
7th, 14th and 21st of the study. On 21st
day blood was collected by retro orbital plexus under mild ether anaesthesia and fasting blood glucose was estimated21.
Serum was separated and analyzed for serum cholesterol22, serum
triglycerides23, serum HDL24, serum LDL24,
serum creatinine25, serum urea26, serum alkaline
phosphatase27, blood glutathione28 by using Span and Erba
diagnostic kits.
2.7
Statistical Analysis:
The results are expressed as mean ± SEM.
Statistical analysis of data among the various groups was performed by using
one way analysis of variance (ANOVA) followed by the Tukey’s
test using Graph Pad Prism software of statistics. Significance value (P<0.05) was considered statistically
significant as compared to control group.
3.
RESULTS:
Effect of Different Types of Drakshasava
on FBG and GSH of Diabetic rats
All types of Drakshasava
as Drakshasava–T, Drakshasava-M
and marketed Drakshasava produced significant (P<0.001) reduction in FBG level in alloxan induced diabetic rats as compared to diabetic
control group as shown in Figure 1(A).
Glibenclamide showed highest significant reduction in
FBG level (60%) as compared to diabetic control group. In our study, in alloxan treated diabetic rats the blood glutathione level
(GSH) was found decreased significantly (P<0.001)
as compared to normal control group as shown in Figure 1(B). Drakshasava-T, Drakshasava-M, marketed
Drakshasava (2 ml/kg p.o.)
and glibenclamide (10 mg/kg p.o)
showed significant increase in GSH level as compared to diabetic control group
on both 14th and 21st day of treatment as shown in Figure 1(B).
Effect of different types of Drakshasava
on body weight of diabetic rats:
All types of Drakshasava
preparations as Drakshasava-T, Drakshasava-M,
marketed Drakshasava and glibenclamide
exhibited significant antihyperglycemic activity in alloxan induced diabetic rats without causing significant
change in body weight as shown in Figure
2.
Effect of different types of Drakshasava
on serum lipid profile of diabetic rats:
Drakshasava-T and Drakshasava-M at the dose of 2ml/kg body weight orally
significantly reduced total serum cholesterol, serum LDL and triglycerides as
compared to diabetic control while significant increase has been observed in
the level of serum HDL in Drakshasava-T and Drakshasava-M treated groups as shown in Figure 3(A). Drakshasava-T
and Drakshasava-M also significantly reduced serum creatinine as shown in Figure
3 (B). All the test preparations of Drakshasava
also showed significant decrease in the level of serum alkaline phosphtase in alloxan induced
diabetic rats as compared to diabetic control group as shown in Figure 3(C). Marketed Drakshasava produced similar effects on the serum lipid
profile of diabetic rats as that of Drakshasava- T
and Drakshasava-M whereas glibenclamide
produced highest reduction in the levels of serum cholesterol, triglyceride and
LDL as well as showed significant improvement in the level of HDL-cholesterol
as compared to diabetic control.
Fig.
1(A) Effect of Drakshasava-T, M and marketed Drakshasava on fasting blood sugar (FBS) level in alloxan induced diabetic albino rats
All values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as compared to normal group
b P<0.001 significant as compared to diabetic control
group
All values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as compared to normal group
b P<0.001 significant as compared to diabetic control
group
Fig. 2 Effect of Drakshasava-T,
M and marketed Drakshasava on the body weight of alloxan induced diabetic albino rats
All values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as
compared to normal group
b P<0.001 significant as
compared to diabetic control group
Fig. 3(A)
Effect of Drakshasava-T, M and marketed Drakshasava on serum lipid profile in alloxan
induced diabetic albino rats
All
values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as compared to normal group, b P<0.001 significant as compared to diabetic control
Fig. 3(B) Effect of Drakshasava-T,
M and marketed Drakshasava on serum creatinine in alloxan induced
diabetic albino rats
All
values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as compared to normal group
b P<0.001 significant as compared to diabetic control
group
Fig. 3(C) Effect of Drakshasava-T,
M and marketed Drakshasava on serum alkaline phosphtase (ALP) in alloxan
induced diabetic albino rats
All
values are expressed as mean ± SEM (n = 6)
a P<0.001 significant as compared to normal group
b P<0.001 significant as compared to diabetic control
group
4. DISCUSSION:
Administration of alloxan
caused rapid destruction of pancreatic ß cells in rats, which led to impaired
glucose stimulated insulin release and insulin resistance, both of which are
marked feature of type II diabetes29. This is because administration
of alloxan (150mg/kg i.p.)
led to more than 1.5 fold elevation of fasting blood glucose level, which was
maintained over a period of three weeks. Three week of daily treatment of Drakshasava-T, Drakshasava-M and
marketed Drakshasava (2ml/kg p.o.)
caused significant fall in blood glucose level.
GSH, being the most important bio-molecule against
chemically induced toxicity can participate in the elimination of reactive
intermediates by reduction of hydro-per-oxidase in
the presence of glutathione per-oxidase. The most
important mechanism implicated in the diabetogenic
action of alloxan is by increased generation of
oxygen free radicals which cause a decrease in plasma GSH concentration. Hence,
drugs that could prevent the generation of these oxygen free radicals or
increase the free radical scavenging enzymes may be effective in alloxan induced diabetes30.
In the present study, the observed significant
increase in blood glucose level and a decrease in blood glutathione levels in
diabetic rats could be due to destruction of ß –cells by alloxan
reinforcing the view that alloxan induced diabetes
probably through the generation of oxygen free radicals31.
The standard anti-diabetic drug glibenclamide
and the test preparations as Drakshasava-T, Drakshasava-M and marketed Drakshasava showed that they could prevent the
development of Diabetes mellitus in albino rats, due to their antioxidant
property since they showed a significant
decrease in fasting blood glucose level (FBG) along with significant increase
in blood glutathione level (GSH) after treatment.
Vehicle control animals were found to be stable in
their body weight but diabetic rats showed significant reduction in body weight
during 21 days. Alloxan caused body weight
reduction, which was improved by standard drug (glibenclamide)
and test preparations (Drakshasava-T, Drakshasava-M and marketed Drakshasava)
nearly equal to the normal.
In general, an increase in blood glucose level is
usually accompanied by an increase in plasma cholesterol, triglyceride, LDL
levels and a decrease in HDL levels as observed in diabetic patients32.
The marked hyperlipidemia that characterizes the
diabetic state may be the consequence of the uninhibited actions of lipolytic hormones on fat depots33. Drakshasava-T, Drakshasava-M,
marketed Drakshasava and standard antidiabetic
glibenclamide produced significant reduction in
fasting blood glucose level. These Drakshasava preparations
and glibenclamide also produced significant reduction
in serum cholesterol, LDL and triglyceride along with significant rise in HDL
level in alloxan induced diabetic rats. Improvement in the lipid profile in diabetic
animals after treatment with Drakshasava-T, Drakshasava-M, marketed Drakshasava
and standard anti-diabetic glibenclamide could be
beneficial in preventing diabetic complications, as well as improving lipid
metabolism in diabetic patients34.
The decrease in FBG level, improvement in the lipid
profile along with significant rise in
the blood glutathione level (GSH) by Drakshasava-T, Drakshasava-M and marketed Drakshasava
in alloxan induced diabetic rats suggests that these
preparations could be useful as an antidiabetic agent with cardio-protective activity. The
obtained result suggests that the presence of alcohol could be beneficial in
the faster absorption of poly-phenolic compounds
found present in Drakshasava which are
responsible for showing scavenging of alloxan induced reactive oxygen species.
5. REFERENCES:
1) Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H , Dandona P. Glucose challenge stimulates reactive oxygen
species (ROS) generation by leucocytes. J Clin Endocrinol Met 2000; 85:2970-2973.
2) Pickup JC, William G. Epidemiology of
Diabetes mellitus. In Textbook of Diabetes. vol.I, 2nd ed.
Blackwell, Oxford; 1997. p. 3.1-3.28.
3) Sagara M, Satoh
J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, MutoY, Toyota
T. Inhibition of development of
peripheral neuropathy in STZ- induced diabetic rats with N-acetylcysteine.
Diabetologia 1996; 53:446-449.
4) Kesari AN, Gupta
RK, Watal G. Hypoglycemic
effects of Murraya koenigii
on normal and alloxan diabetic rabbits. J Ethnopharmacol
2005; 97: 247-251.
5) Davidson MB. Diabetes
mellitus Diagnosis and treatment. New York: Wiley; 1981. p. 27-48.
6) The Ayurvedic
Formulary of India, Part-II, 2000, 1st edition, The Controller of
Publications, Delhi, p.35.
7) Baydar NG, Ozkan G, Sagdic O. Total phenolic contents and antibacterial activities of grape (Vitis vinifera L.)
extracts. Food Control 2004; 15:335-339.
8) Akoh CC, Bonilla
EP, Sellappan S, Krewer G. Phenolic content and antioxidant capacity of Muscadine grapes. Journal of Agricultural
and Food Chemistry 2003; 51:5497-5503.
9) Frankel EN, Kanner
J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. The Lancet 1993;
341(20):454-457.
10) Mayer AS, Yi OS, Person DA, Waterhouse DL, Frankel
EN. Inhibition of human low density lipoprotein oxidation in
relation to composition of phenolic antioxidants in
grapes (Vitis vinifera).
Journal of Agricultural and Food Chemistry 1997;
45:1638-1643.
11) Teissedre PL, Frankel EN, Waterhouse AL, Peleg H, German GB. Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines. Journal of the Science of Food and Agriculture 1996; 70:55-61.
12) Waterhouse AL. Wine antioxidants may reduce
heart disease and cancer. Presentation of American Chemical
Society, Washington; 1994.
13) Renaud S, Lorgeril MD. Wine, alcohol, platelets and
the French paradox for coronary heart disease. The
Lancet 1992; 339:1523-1526.
14) Davalos A, Bortolome B, Gomez-cordoves C.
Antioxidant properties of commercial grape juices and vinegars. Food Chemistry
2005; 93(2):325-330.
15) Orhan DD, Orhan N, Ergun E, Ergun F. Hepatoprotective
effect of Vitis vinifera
L. leaves on carbon tetrachloride-induced acute liver damage in rats. Jornal of Ethnopharmacology 2007;
112:145-151.
16) Corder R, Mullen
W, Khan NQ, Marks SC, Wood EG, Carrier MJ, Crozier
A. Red wine procyanidins and vascular health. Nature 2006;444:566.
17) Mishra S. Bhaisazya Kalpana Vigyan. Varanasi, India: Chaukambha
Surbharati Prakashan;
2005.p. 253-254.
18) Alam M, Radhamani S, Ali U, Purushottam
KK. Microbiological Screening of Dhataki
Flowers. Journal of Research in Ayurveda and Siddha 1984; 2(4):371-375.
19) Nishikant AR, Naresh JG. Antidiabetic Activity
of hydro-ethanolic extract of Cyperus
rotundus in alloxan
induced Diabetes in rats. Fitoterapia 2006;
77:585-588.
20) Sharma SR, Dwivedi
SK, Swarup D. Hypoglycemic
and hypolipidemic effects of Cinnamomum
tamala Nees leaves. Indian J Exp Biol 1996; 34:372-374.
21) Giordano BP, Thrash W, Hollenbaugh
L, Dube WP, Hodges C, Swain A, Banion
CR , Klingensmith GJ. Performance
of seven blood glucose testing systems at high altitude. Diabet Educa 1989; 15: 444-448.
22) Allain CC, Poon LS, Chan CS, Richmond W. Enzymatic Determination of
Total Serum cholesterol. Clin Chem
1974; 20: 471-475.
23) Muller PH, Schmulling
RM, Liebich HM, Eggstein M.
A fully Enzymatic Triglyceride Determination. J Clin Chem 1977;
15: 457-464.
24) Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-density lipoprotein
cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25) Bowers LD. Kinetic Serum Creatinine
Assay. The role of various factors in determining
specificity. Clin Chem 1980; 26: 551-554.
26) Wilson BW. Automatic
Estimation of urea using urease and alkaline phenol.
Clin Chem 1966; 12: 360-368.
27) Sasaki MA. New method for
the determination of serum alkaline phosphatase.
Use of Berthelot’s reaction for the estimation of phenol
released by enzymatic activity. Igaku To Seibutsugaku 1966; 70:
208-214.
28) Beutler E, Duron O, Kelly BM. Improved method for determination of
blood glutathione. J Lab Med 1963; 61:882-888.
29) Proks P, Reimann F, Gribble F. Sulfonyl
urea stimulation in insulin secretion. Diabetes 2002; 51: S368-76.
30) Shankar PK, Kumar V, Rao
N. Evaluation of Anti-diabetic activity of Ginkgo biloba
in streptozotocin induced Diabetic Rats. Iranian J Pharmacol Therapeutics 2005; 4: 16-19.
31) Wohaleb SA, Godin DV. Alterations in free radical tissue defence
mechanism in streptozotocin induced diabetes in rat.
Diabetes 1987; 36: 1014-1018.
32) Mitra SK, Gopumadhvans, Muralidhar TS, Anturlikar SD, Sujatha MB. Effect
of D-400, a mineraloherbal preparation on lipid
profile, glycosylated haemoglobin and glucose
tolerance in streptozotocin induced diabetic rats. Indian J Exp Biol 1995; 33: 798-800.
33) Bopanna KN, Kanna J, Sushma G, Balaram R, Rathod SP. Antidiabetic and antihyperlipidemic
effects of neem seed kernel powder on alloxan diabetic rabbits. Indian J Pharmacol 1997; 29:162-7.
34) Cho SY, Park JY, Park EM. Alteration of
hepatic antioxidant enzyme activities and lipid profile in streptozotocin
induced diabetic rats by supplementation of dandelion water extract. Clin Chem Acta
2002; 317: 109-117
Received on 17.01.2013
Modified on 01.02.2013
Accepted on 09.02.2013
© A&V Publication
all right reserved
Research
Journal of Pharmacognosy and Phytochemistry. 5(2): March-April 2013,
87-93